Survival is associated with time to reach PSA nadir (DAN) and the ratio DAN/nadir value after androgen deprivation for prostate cancer;La survie est associée au délai d'atteinte du PSA, nadir (DAN) et au ratio DAN/valeur nadir après, suppression androgénique pour cancerde prostate

Progres en Urologie

Volumn 21, Issue 5, 2011, Pages 341-348

  Gagnat, A ^a   Larre S ^b   Fromont, G ^a   Pires C ^a   Dore B ^a   Irani, J ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Prostate cancer; Prostate specific antigen kinetics; Time to prostate specific antigen nadir

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; HUMAN; MALE; MORTALITY; PROSTATE TUMOR; SURVIVAL RATE; TIME;

ANDROGEN ANTAGONISTS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 79955020371     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2010.09.024     Document Type: Article

References (13)

1. Soulié M., Beuzeboc P., Cornud F., Eschwege P., Gaschignard N., Grosclaude P., et al. Recommandations 2007 en onco-urologie. Prog Urol 2007, 17(6):1188-1230.
2. Heidenreich A., Aus G., Bolla M., Joniau S., Matveev V.B., Schmid H.P., et al. EAU guidelines on prostate cancer. Eur Urol 2008, 53:68-80.
3. Kwak C., Jeong S.J., Park M.S., Lee E., Lee S.E. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002, 168:995-1000.
4. Choueiri T.K., Xie W., D'Amico A.V., Ross R.W., Hu J.C., Pomerantz M., et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009, 115:981-987.
5. Normand G., Celhay O., Briffaux R., Pirès C., Doré B., Irani J. Pourcentage de biopsies positives chez les patients traités par hormonothérapie pour cancer de la prostate: valeur pronostique. Prog Urol 2009, 19:321-326.
6. Collette L., Burzykowski T., Carroll K.J., Newling D., Morris T., Schroder F.H. Is prostate-specific antigen a valid surrogate endpoint for survival in hormonally treated patients with metastatic prostate cancer Joint research of the European organisation for research and treatment of cancer, the Limburgs Universitair Centrum, and AstraZeneca pharmaceuticals. J Clin Oncol 2005, 23:6139-6148.
7. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest oncology group trial 9346 (INT-0162). J Clin Oncol 2006, 24:3984-3990.
8. Sharifi N., Dahut W.L., Figg W.D. Secondary hormonal therapy for prostate cancer: what lies on the horizon BJU Int 2008, 101:271-274.
9. Robinson D., Sandblom G., Johansson R., Garmo H., Stattin P., Mommsen S., et al. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J Urol 2008, 179:117-122.
10. Nayyar R., Sharma N., Gupta N.P. Prognostic factors affecting progression and survival in metastatic prostate cancer. Urol Int 2010, 84:159-163.
11. Hori S., Jabbar T., Kachroo N., Vasconcelos J.C., Robson C.N., Gnanapragasam V.J. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol 2010, 10.1007/s00432-010-0877-9.
12. Petrylak D.P., Ankerst D.P., Jiang C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006, 98:516521.
13. Lin G.W., Yao X.D., Zhang S.L., Dai B., Ma C.G., Zhang H.L., et al. Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian J Androl 2009, 11:443-450.